Anaplastic Lymphoma Kinase Gene Translocation

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Anaplastic Lymphoma Kinase Gene Translocation trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 4

NCT05525338

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

The ADAPT ALEC randomized controlled trial (RCT) is performed in patients with Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC). The…

France, Netherlands196 participantsStarted 2022-03-23

Treatment: Alectinib

All recent trials (17 shown)

Active — Not RecruitingNot Applicable

NCT04881916

Immune and Genomic Markers in ALK+ NSCLC

The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymph…

United States100 participantsStarted 2021-12-01

Active — Not RecruitingPhase 2

NCT04223596

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

This is an open-label, non-randomised, phase II, exploratory, multi-country and multi-centre clinical trial. Chemotherapy-naïve patients with EML4-ALK rearrange…

Spain33 participantsStarted 2020-05-04

Treatment: Brigatinib

Anaplastic Lymphoma Kinase Gene Translocation

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

All recent trials (17 shown)

Immune and Genomic Markers in ALK+ NSCLC

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

All recent trials (17 shown)

Immune and Genomic Markers in ALK+ NSCLC

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK F…

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Endobronchial Ultrasound Needle Aspiration With and Without Suction

Lorlatinib Combinations in Lung Cancer

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Transloca…

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Pat…

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

IPI-504 in NSCLC Patients With ALK Translocations

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplati…

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Speci…

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell L…

A+C in Metastatic Lung Adenocarcinoma Cancer

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (A…